Related Experiment Videos
Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy--clinical
1Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA. paul_renhowe@cc.chiron.com
Abstract:
Aberrant signal transduction plays a major role in the pathophysiology of cancer. Kinases, key enzymes involved in signaling pathways, are attractive targets for chemotherapeutic intervention in the fight against cancer. Many cancers respond to endogenous growth factors or, through autocrine loops, express growth factors and the requisite receptor kinases, resulting in cellular proliferation. Growth factor-induced signaling has also been implicated in the activation of anti-apoptotic cell survival pathways. This review attempts to describe some of the key advances made in the last year towards the design and development of inhibitors of growth factor receptor kinases. Particular emphasis is placed on ATP-competitive, small molecule inhibitors of this important class of enzymes.
Insights
Researchers are developing new small molecule inhibitors targeting growth factor receptor kinases, crucial enzymes in cancer cell growth and survival. These targeted therapies offer a promising avenue for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Aberrant signal transduction is central to cancer pathophysiology.
- Kinases are key enzymes in cancer signaling pathways and therapeutic targets.
- Growth factor receptor kinases drive cancer proliferation and survival.
Purpose of the Study:
- To review recent advances in the design and development of growth factor receptor kinase inhibitors.
- To highlight ATP-competitive, small molecule inhibitors.
Main Methods:
- Literature review focusing on the last year's advancements.
- Emphasis on small molecule, ATP-competitive kinase inhibitors.
Main Results:
- Significant progress in developing targeted inhibitors for growth factor receptor kinases.
- Focus on small molecules that compete with ATP binding.
Conclusions:
- Growth factor receptor kinase inhibitors represent a key strategy in cancer therapy.
- Continued development of small molecule inhibitors shows promise for effective cancer treatment.